Continuous glucose monitoring (CGM) technology has transformed diabetes management by offering real-time insights into glycemic trends. A groundbreaking study now establishes a clear link between CGM and mortality reduction in older-onset type 1 diabetes (T1D) patients. While clinicians traditionally use CGM to optimize HbA1c and prevent hypoglycemia, its impact on survival was previously less clear. This new target trial emulation within the Veterans Health Administration provides compelling evidence that technology initiation significantly lowers the risk of death.

Evidence for CGM and Mortality Reduction

The researchers analyzed data from over 8,400 veterans to compare mortality rates between CGM users and non-users. Consequently, they found that initiating CGM correlated with a 10% to 16% lower risk of all-cause mortality over a four-year follow-up period. Interestingly, the survival advantage appeared most pronounced in patients older than 65 years. Furthermore, those not using insulin pumps experienced similar life-prolonging benefits. These results suggest that the protective effects of CGM extend beyond just glycemic metrics to overall patient longevity.

Moreover, the study rigorously accounted for potential biases through inverse probability weighting and negative outcome controls. Specifically, the researchers found no differences in unrelated medical conditions between groups, which reinforces that the mortality benefit relates directly to CGM use. Notably, factors like race, ethnicity, or frailty did not alter these positive outcomes. Therefore, healthcare providers should view CGM as a primary intervention for improving survival in the aging T1D population. By providing a safety net against acute events, this technology effectively serves as a life-saving tool.

Frequently Asked Questions

How does CGM improve survival in older T1D patients?

CGM provides real-time alerts for impending hypoglycemia and hyperglycemia. By preventing severe acute glycemic events, the technology likely reduces the risk of cardiovascular complications and other mortality-linked emergencies common in older adults.

Can CGM benefit patients who do not use insulin pumps?

Yes, the study specifically noted that patients not on insulin pumps showed a significant reduction in mortality. This makes CGM a valuable tool for all T1D patients on intensive insulin therapy, regardless of their delivery method.

Does the mortality benefit depend on a patient's baseline HbA1c?

The research indicated that the reduction in mortality did not vary by HbA1c levels. This suggests that even patients with relatively stable average glucose can benefit from the continuous oversight provided by CGM sensors.

Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Reaven PD et al. Continuous Glucose Monitoring (CGM) Initiation Is Associated With Reduced Mortality in Older-Onset Type 1 Diabetes Patients: A Target Trial Emulation Study Within the Veterans Health Administration. Diabetes Care. 2026 Jun 19. doi: undefined. PMID: 42319755.

Beck RW, Riddlesworth T, Anderson K, et al. Effect of Continuous Glucose Monitoring on Glycemic Control in Adults With Type 1 Diabetes Using Insulin Injections: The DIAMOND Randomized Clinical Trial. JAMA. 2017;317(4):371-378.